The stock of PhaseRx Inc (NASDAQ:PZRX) is a huge mover today! About 56,577 shares traded hands or 41.15% up from the average. PhaseRx Inc (NASDAQ:PZRX) has risen 6.00% since September 5, 2016 and is uptrending. It has underperformed by 2.26% the S&P500.
The move comes after 7 months negative chart setup for the $26.17 million company. It was reported on Oct, 5 by Barchart.com. We have $2.14 PT which if reached, will make NASDAQ:PZRX worth $2.88 million less.
Analysts await PhaseRx Inc (NASDAQ:PZRX) to report earnings on November, 1. After $-0.59 actual EPS reported by PhaseRx Inc for the previous quarter, Wall Street now forecasts -66.10% EPS growth.
According to Zacks Investment Research, “PhaseRx, Inc. is a preclinical biopharmaceutical company. It is engaged in developing products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The Company’s i-ERT approach is enabled by its proprietary Hybrid mRNA Technology(TM) platform. PhaseRx, Inc. is headquartered in Seattle, Wash.”
More notable recent PhaseRx Inc (NASDAQ:PZRX) news were published by: Marketwatch.com which released: “PhaseRx Inc.” on May 18, 2016, also Prnewswire.com with their article: “PhaseRx to Present at the 2016 Aegis Growth Conference” published on September 14, 2016, Prnewswire.com published: “PhaseRx Appoints Peggy Phillips to Board of Directors” on August 22, 2016. More interesting news about PhaseRx Inc (NASDAQ:PZRX) were released by: Prnewswire.com and their article: “PhaseRx Announces Pricing of Initial Public Offering” published on May 18, 2016 as well as Prnewswire.com‘s news article titled: “PhaseRx Advances Product Pipeline for Treatment of Rare Genetic Liver Diseases” with publication date: June 21, 2016.
PZRX Company Profile
PhaseRx, Inc. is a biopharmaceutical firm developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood. The Company’s i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Firm is headquartered in Seattle.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.